TRAF1 antibody (AA 73-219)

Catalog No. ABIN6938673

The Mouse Monoclonal anti-TRAF1 antibody has been validated for IHC and IHC (f). It is suitable to detect TRAF1 in samples from Human.

Quick Overview for TRAF1 antibody (AA 73-219) (ABIN6938673)

Target: TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TRAF1 antibody is un-conjugated

Application: Immunohistochemistry (IHC), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))

Clone: TRAF1-3298

Product Details anti-TRAF1 Antibody

Binding Specificity: AA 73-219

Specificity: This MAb recognizes a protein of 52 kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30 % of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84 %) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7 %). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.

Cross-Reactivity (Details): Human.

Purification: 1.0mg/ml of Ab purified from Bioreactor by Protein A/G.

Immunogen: Recombinant fragment of human TRAF1 protein (around aa 73-219) (exact sequence is proprietary)

Isotype: IgG2b kappa

Application Details

Application Notes:

Known_Application: Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT) ,(Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes), Optimal dilution for a specific application should be determined.

Positive_Control: HeLa or 293T cells. Hodgkin s Lymphoma (IHC).

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: Prepared in 10 mM PBS, WITHOUT BSA and Azide.

Preservative: Azide free

Storage: -20 °C,-80 °C

Storage Comment: Antibody without azide store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous.

Expiry Date: 24 months

Target Details for TRAF1

Target: TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Alternative Name: TRAF1

Background: EBI6, EBV induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1, TRAF1,TRAF1 (TNFR-Associated Factor 1) (Lymphomatoid Papulosis Marker)
Cellular localisation: Cytoplasmic

Molecular Weight: 52kDa

Gene ID: 7185, 531251

UniProt: Q13077

Pathways: NF-kappaB Signaling, Apoptosis, Cell-Cell Junction Organization, Asymmetric Protein Localization